Biotech Industry Fears Fallout From Supreme Court’s Myriad Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Supreme Court unanimously holds that DNA isolated from the human body cannot be patented but cDNA, which is created in a laboratory, can be; says Myriad “did not create anything.”
You may also be interested in...
Gene Patents: Supreme Court Could Be Swayed By Impact On Research
The outcome of ACLU’s suit challenging Myriad Genetics’ BRCA cancer genes is crucial for the biotech industry as it could prevent companies from getting patents on therapeutics that utilize DNA and other isolated molecules.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.